[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE9802864D0 - Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder - Google Patents

Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Info

Publication number
SE9802864D0
SE9802864D0 SE9802864A SE9802864A SE9802864D0 SE 9802864 D0 SE9802864 D0 SE 9802864D0 SE 9802864 A SE9802864 A SE 9802864A SE 9802864 A SE9802864 A SE 9802864A SE 9802864 D0 SE9802864 D0 SE 9802864D0
Authority
SE
Sweden
Prior art keywords
overactive bladder
tolterodine
treatment
antimuscarinic agent
transdermally administered
Prior art date
Application number
SE9802864A
Other languages
English (en)
Inventor
Lene Orup Jacobsen
Bo Kreilgaard
Ulla Hoeck
Helle Kristensen
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412370&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9802864(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Priority to SE9802864A priority Critical patent/SE9802864D0/sv
Publication of SE9802864D0 publication Critical patent/SE9802864D0/sv
Priority to IL15641499A priority patent/IL156414A0/xx
Priority to MYPI99003665A priority patent/MY127946A/en
Priority to DE69942928T priority patent/DE69942928D1/de
Priority to PT99946521T priority patent/PT1039882E/pt
Priority to DK99946521.4T priority patent/DK1039882T3/da
Priority to AT99946522T priority patent/ATE405254T1/de
Priority to NZ509928A priority patent/NZ509928A/en
Priority to EP99946522A priority patent/EP1105111B1/en
Priority to CA2311755A priority patent/CA2311755C/en
Priority to ES99946522T priority patent/ES2310942T3/es
Priority to ARP990104280A priority patent/AR029311A1/es
Priority to APAP/P/2000/001823A priority patent/AP1529A/en
Priority to US09/582,498 priority patent/US6770295B1/en
Priority to SK749-2000A priority patent/SK287111B6/sk
Priority to TR2000/01998T priority patent/TR200001998T1/xx
Priority to ES99946521T priority patent/ES2353765T3/es
Priority to JP2000567189A priority patent/JP2002523446A/ja
Priority to PCT/SE1999/001463 priority patent/WO2000012069A1/en
Priority to CNB99801916XA priority patent/CN1239152C/zh
Priority to DE69939382T priority patent/DE69939382D1/de
Priority to IDP20001006A priority patent/ID25824A/id
Priority to US09/763,654 priority patent/US6517864B1/en
Priority to EP99946521A priority patent/EP1039882B1/en
Priority to GE3951A priority patent/GEP20043354B/en
Priority to PCT/SE1999/001464 priority patent/WO2000012070A1/en
Priority to OA1200000309A priority patent/OA11636A/en
Priority to CZ20001924A priority patent/CZ302630B6/cs
Priority to AU58919/99A priority patent/AU758399B2/en
Priority to EP09173927A priority patent/EP2153825A1/en
Priority to NZ504618A priority patent/NZ504618A/xx
Priority to IL13629499A priority patent/IL136294A/en
Priority to EA200000468A priority patent/EA002720B1/ru
Priority to SI9931050T priority patent/SI1039882T1/sl
Priority to AT99946521T priority patent/ATE487471T1/de
Priority to MEP-2001-331A priority patent/ME00850B/me
Priority to CA002341063A priority patent/CA2341063C/en
Priority to UA2000052950A priority patent/UA72882C2/uk
Priority to HU0100437A priority patent/HUP0100437A3/hu
Priority to AU58918/99A priority patent/AU745190B2/en
Priority to TW088114752A priority patent/TWI253349B/zh
Priority to ZA200002488A priority patent/ZA200002488B/xx
Priority to BG104476A priority patent/BG65168B1/bg
Priority to NO20002977A priority patent/NO329830B1/no
Priority to IS5537A priority patent/IS2976B/is
Priority to HK01104868A priority patent/HK1034664A1/xx
Priority to US10/301,719 priority patent/US7008637B2/en
Priority to CY20101101027T priority patent/CY1111088T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9802864A 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder SE9802864D0 (sv)

Priority Applications (48)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
IL15641499A IL156414A0 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
MYPI99003665A MY127946A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
DE69942928T DE69942928D1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
PT99946521T PT1039882E (pt) 1998-08-27 1999-08-26 Formulação terapêutica para administrar tolterodina com libertação controlada
DK99946521.4T DK1039882T3 (da) 1998-08-27 1999-08-26 Terapeutisk formulering til indgivelse af tolterodin med kontrolleret frigivelse
AT99946522T ATE405254T1 (de) 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase
NZ509928A NZ509928A (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
EP99946522A EP1105111B1 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
CA2311755A CA2311755C (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
ES99946522T ES2310942T3 (es) 1998-08-27 1999-08-26 Tolterodina administrada por via transdermica como agente anti-muscarinico para el tratamiento de vejiga hiperactiva.
ARP990104280A AR029311A1 (es) 1998-08-27 1999-08-26 UN MÉTODO PARA EL TRATAMIENTO DE LA VEJIGA URINARIA INESTABLE O HIPERACTIVA CON UNA FORMULACIoN DE LIBERACIoN CONTROLADA DE TOLTERODINA O COMPUESTOS RELACIONADOS; DICHA FORMULACIoN FARMACÉUTICA Y USO DE TOLTERODINA O DE COMPUESTOS RELACIONADOS.
APAP/P/2000/001823A AP1529A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.
US09/582,498 US6770295B1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
SK749-2000A SK287111B6 (sk) 1998-08-27 1999-08-26 Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním
TR2000/01998T TR200001998T1 (tr) 1998-08-27 1999-08-26 Kontrollü salıverilen tolterodin uygulamak için ilaç formülasyonu
ES99946521T ES2353765T3 (es) 1998-08-27 1999-08-26 Formulación terapeútica para administrar tolterodina con liberación controlada.
JP2000567189A JP2002523446A (ja) 1998-08-27 1999-08-26 過活動性膀胱の治療のための抗ムスカリン剤としての経皮投与トルテロジン
PCT/SE1999/001463 WO2000012069A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
CNB99801916XA CN1239152C (zh) 1998-08-27 1999-08-26 控释给药托耳替罗地的治疗制剂
DE69939382T DE69939382D1 (de) 1998-08-27 1999-08-26 Transdermal verabreichtes tolterodin als antimuskarin-wirkstoff zur behandlung der hyperaktiven blase
IDP20001006A ID25824A (id) 1998-08-27 1999-08-26 Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
US09/763,654 US6517864B1 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
EP99946521A EP1039882B1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
GE3951A GEP20043354B (en) 1998-08-27 1999-08-26 Therapeutic Formulation for Administering Tolterodine with Controlled Release
PCT/SE1999/001464 WO2000012070A1 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
OA1200000309A OA11636A (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release.
CZ20001924A CZ302630B6 (cs) 1998-08-27 1999-08-26 Farmaceutický prostredek obsahující tolterodin nebo tolterodinu príbuznou slouceninu
AU58919/99A AU758399B2 (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
EP09173927A EP2153825A1 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
NZ504618A NZ504618A (en) 1998-08-27 1999-08-26 Controlled release therapeutic formulation for administering tolterodine maintaining a constant serum level
IL13629499A IL136294A (en) 1998-08-27 1999-08-26 Use of toltrodine, 5-hydroxy methyl metabolite or its resmat in the preparation of drugs for the treatment of unstable or overactive bladder
EA200000468A EA002720B1 (ru) 1998-08-27 1999-08-26 Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
SI9931050T SI1039882T1 (sl) 1998-08-27 1999-08-26 Terapevtska formulacija za dajanje tolterodina s kontroliranim sproščanjem
AT99946521T ATE487471T1 (de) 1998-08-27 1999-08-26 Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
MEP-2001-331A ME00850B (me) 1998-08-27 1999-08-26 Nove perle sa kontrolisanim oslobađanjem, postupak za njihovu proizvodnju i višestruka jedinična formulacija koja ih sadrži
CA002341063A CA2341063C (en) 1998-08-27 1999-08-26 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
UA2000052950A UA72882C2 (uk) 1998-08-27 1999-08-26 Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину
HU0100437A HUP0100437A3 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
AU58918/99A AU745190B2 (en) 1998-08-27 1999-08-26 Therapeutic formulation for administering tolterodine with controlled release
TW088114752A TWI253349B (en) 1998-08-27 1999-08-27 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
ZA200002488A ZA200002488B (en) 1998-08-27 2000-05-19 Therapeutic formulation for administering tolterodine with controlled release.
BG104476A BG65168B1 (bg) 1998-08-27 2000-05-26 Фармацевтична форма на толтеродин с контролирано освобождаване
NO20002977A NO329830B1 (no) 1998-08-27 2000-06-09 Oral farmasoytisk formulering inneholdende tolterodin og med kontrollert frigivelse
IS5537A IS2976B (is) 1998-08-27 2000-06-15 Lyfjablanda til inntöku um munn sem inniheldur tolteródín og hefur stýrða losun
HK01104868A HK1034664A1 (en) 1998-08-27 2001-07-12 Therapeutic formulation for administering tolterodine with controlled release
US10/301,719 US7008637B2 (en) 1998-08-27 2002-11-22 Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder
CY20101101027T CY1111088T1 (el) 1998-08-27 2010-11-17 Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Publications (1)

Publication Number Publication Date
SE9802864D0 true SE9802864D0 (sv) 1998-08-27

Family

ID=20412370

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9802864A SE9802864D0 (sv) 1998-08-27 1998-08-27 Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Country Status (13)

Country Link
US (2) US6517864B1 (sv)
EP (1) EP1105111B1 (sv)
JP (1) JP2002523446A (sv)
AT (1) ATE405254T1 (sv)
AU (1) AU758399B2 (sv)
CA (1) CA2341063C (sv)
DE (1) DE69939382D1 (sv)
ES (2) ES2353765T3 (sv)
NZ (1) NZ509928A (sv)
SE (1) SE9802864D0 (sv)
TW (1) TWI253349B (sv)
WO (1) WO2000012070A1 (sv)
ZA (1) ZA200002488B (sv)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0924983A4 (en) * 1996-07-19 1999-08-25 Gunnar Aberg S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
DE69901284T2 (de) 1999-01-27 2002-11-28 Idea Ag Transnasaler Transport bzw. Impfung mit hochadaptierbaren Trägern
DE19922662C1 (de) * 1999-05-18 2000-12-28 Sanol Arznei Schwarz Gmbh Transdermales therapeutisches System (TTS) Tolterodin enthaltend
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
DE19932651A1 (de) * 1999-07-13 2001-01-18 Hexal Ag Transdermales therapeutisches System zur Anwendung von Tolterodin
EP1455697A4 (en) * 2001-12-20 2009-08-05 Femmepharma Holding Co Inc VAGINAL DRUG DELIVERY
MXPA05007266A (es) * 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20040191345A1 (en) * 2003-03-26 2004-09-30 Fredrik Nicklasson New formulations and use thereof
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
JP5548329B2 (ja) * 2003-08-04 2014-07-16 杏林製薬株式会社 経皮吸収型製剤
WO2006015299A2 (en) * 2004-07-30 2006-02-09 Microchips, Inc. Multi-reservoir device for transdermal drug delivery and sensing
KR101312814B1 (ko) * 2005-02-03 2013-09-27 오노 야꾸힝 고교 가부시키가이샤 경피 흡수형 제제
EP1951186A4 (en) 2005-10-19 2009-11-04 Menni Menashe Zinger METHODS FOR TREATING HYPERHIDROSIS
AU2007238685B2 (en) * 2006-04-13 2012-09-13 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
AU2012261753B2 (en) * 2006-04-13 2015-03-05 Teva Pharmaceuticals International Gmbh Transdermal methods and systems for the delivery of anti-migraine compounds
WO2007140191A2 (en) 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080153789A1 (en) * 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
US20080193766A1 (en) * 2007-02-13 2008-08-14 Northern Nanotechnologies Control of Transport to and from Nanoparticle Surfaces
US7838498B2 (en) 2007-04-02 2010-11-23 Theracos, Inc. Benzylic glycoside derivatives and methods of use
US8871275B2 (en) 2007-08-08 2014-10-28 Inventia Healthcare Private Limited Extended release compositions comprising tolterodine
US7838499B2 (en) 2007-08-23 2010-11-23 Theracos, Inc. Benzylbenzene derivatives and methods of use
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090297591A1 (en) * 2008-05-30 2009-12-03 Orient Pharma Co., Ltd. Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds
CN102099475A (zh) * 2008-06-04 2011-06-15 科达治疗公司 用间隙连接调节化合物治疗疼痛
US8366600B2 (en) * 2008-06-19 2013-02-05 Nupathe Inc. Polyamine enhanced formulations for triptan compound iontophoresis
US8155737B2 (en) 2008-06-19 2012-04-10 Nupathe, Inc. Pharmacokinetics of iontophoretic sumatriptan administration
TWI523652B (zh) 2008-07-15 2016-03-01 泰瑞克公司 氘化苄基苯衍生物及使用方法
CA2734295C (en) 2008-08-22 2016-12-20 Theracos, Inc. Processes for the preparation of sglt2 inhibitors
AU2009324894B2 (en) 2008-11-25 2015-04-09 University Of Rochester MLK inhibitors and methods of use
WO2010150100A1 (en) 2009-06-24 2010-12-29 Entarco Sa The use of spinosyns and spinosyn compositions against diseases caused by protozoans, viral infections and cancer
KR20110001103A (ko) * 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
BR112012003111A8 (pt) * 2009-08-10 2017-10-10 Nupathe Inc Métodos para tratar iontoforeticamente náusea e enxaqueca
WO2011046927A1 (en) * 2009-10-13 2011-04-21 Nupathe,Inc. Transdermal methods and systems for the delivery of rizatriptan
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
KR101746204B1 (ko) * 2010-02-18 2017-06-13 에스케이케미칼주식회사 피부 투과가 개선된 톨테로딘의 경피 투여용 조성물
KR20110094858A (ko) * 2010-02-18 2011-08-24 에스케이케미칼주식회사 피부 자극이 감소한 톨테로딘의 경피 투여용 조성물
EP2564873A4 (en) * 2010-04-28 2013-11-06 Hisamitsu Pharmaceutical Co MEANS FOR THE SUPPRESSION OF SKIN IRRITATIONS AND TRANSDERMAL PREPARATION THEREOF
CA2800176C (en) 2010-05-24 2018-08-28 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2012017892A1 (ja) 2010-08-03 2012-02-09 久光製薬株式会社 貼付剤及びその粘着力増強方法
EP2654757A1 (en) 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
CA2868334C (en) 2011-12-27 2020-03-10 Teikoku Seiyaku Co., Ltd. Tolterodine-containing adhesive patch
JP2015513905A (ja) 2012-03-27 2015-05-18 コーダ セラピューティクス， インコーポレイテッド カドヘリン調節に基づく組成物および処置
EP2849774A4 (en) 2012-05-18 2015-11-25 Otago Innovation Ltd COMBINATION TREATMENTS AND COMPOSITIONS FOR WOUND HEALING
PL2859892T3 (pl) 2012-06-12 2023-10-16 KM Transderm Ltd. Plaster
US9895320B2 (en) 2012-09-28 2018-02-20 KM Transderm Ltd. Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer
WO2014085795A1 (en) 2012-11-30 2014-06-05 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
CN103142465B (zh) * 2013-03-19 2014-10-22 长春健欣生物医药科技开发有限公司 一种托特罗定成膜水凝胶制剂及其制备方法
JP6566444B2 (ja) 2014-03-19 2019-08-28 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ２−（アシルアミノ）イミダゾールを含む組成物および方法
US9987361B1 (en) 2014-12-29 2018-06-05 Noven Pharmaceuticals, Inc. Compositions and method for sustained drug delivery by active transdermal technology
EP3601232B1 (en) 2017-03-31 2022-11-23 Curza Global LLC Compositions and methods comprising substituted 2-aminoimidazoles
EP3841123A2 (en) 2018-08-23 2021-06-30 Seagen Inc. Anti-tigit antibodies
WO2022020670A1 (en) * 2020-07-23 2022-01-27 Kimberly-Clark Worldwide, Inc. Method for modulating the bladder microbiome to improve bladder health
KR20230104659A (ko) 2020-11-08 2023-07-10 씨젠 인크. 면역 세포 억제제를 이용한 조합-요법 항체 약물 접합체
CA3216170A1 (en) 2021-04-09 2022-10-13 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
WO1993023025A1 (en) 1992-05-13 1993-11-25 Alza Corporation Transdermal administration of oxybutynin
EP0924983A4 (en) * 1996-07-19 1999-08-25 Gunnar Aberg S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
AU709580B2 (en) * 1996-08-09 1999-09-02 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
SE9802864D0 (sv) * 1998-08-27 1998-08-27 Pharmacia & Upjohn Ab Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder

Also Published As

Publication number Publication date
ATE405254T1 (de) 2008-09-15
US7008637B2 (en) 2006-03-07
AU5891999A (en) 2000-03-21
JP2002523446A (ja) 2002-07-30
NZ509928A (en) 2003-08-29
CA2341063A1 (en) 2000-03-09
ES2353765T3 (es) 2011-03-04
CA2341063C (en) 2008-02-12
TWI253349B (en) 2006-04-21
ES2310942T3 (es) 2009-01-16
EP1105111B1 (en) 2008-08-20
ZA200002488B (en) 2001-05-16
DE69939382D1 (de) 2008-10-02
AU758399B2 (en) 2003-03-20
US6517864B1 (en) 2003-02-11
US20030124179A1 (en) 2003-07-03
EP1105111A1 (en) 2001-06-13
WO2000012070A1 (en) 2000-03-09

Similar Documents

Publication Publication Date Title
SE9802864D0 (sv) Transdermally administered tolterodine as antimuscarinic agent for the treatment of overactive bladder
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
MXPA05004381A (es) Estereoisomeros de para-hidroxi-milnacipran y metodos de uso de los mismos.
DE60018797D1 (de) Hydroxide freisetzende verbindungen zum verbessern der hautdurchlässigkeit
HUP0204229A2 (hu) Orális opioid készítmények, eljárás az előállításukra és alkalmazásuk
EE05420B1 (et) Fentanli kompositsioon ninasiseseks manustamiseks
WO2003068171A3 (en) Method and composition for treatment of inflammation and aids-associated neurological disorders
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
IS2789B (is) Lyfjablöndur sem innihalda mónóamínoxídasa B hemla
HUP0300833A2 (hu) Gabapentin analogonok alvászavarok kezelésére
SE9601528D0 (sv) Transdermally administered dextromethorphan as antitissue agent
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0005797A (pt) Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
DK1091733T3 (da) (-)-Pseudoephedrin som et sympatomimetisk lægemiddel
SE0004101D0 (sv) New use
HUP0203050A2 (hu) Endometriózis és meddőség kezelésére, valamint a termékenység fokozására alkalmas gyógyszerkészítmények
HUP0402326A2 (hu) Gyógyszerkészítmény addikció megelőzésére fájdalom kezelésében
BRPI0407569A (pt) uso de s-10-hidróxi-10, 11-diidro-carbamazepina para o tratamento de ansiendade e distúrbios bipolares
TR200102087T2 (tr) Yeni morfolinbenzamid tuzları
MXPA04010658A (es) Tratamiento de dolor con ifenprodil.
MA27538A1 (fr) Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol
EP1011672A4 (en) CONNECTIONS WITH ANALGETIC EFFECT AND COMPILATIONS THAT CONTAIN THEM
DK200300110A (da) Pharmaceutical kit for nasal administration